A B S T R A C T
Most patients with anti-glomerular basement membrane (anti-GBM) disease present with rapidly progressive glomerulonephritis with or without pulmonary haemorrhage; however, there are several variants and vigilance is necessary to make a correct diagnosis. Such variants include overlap with antineutrophil cytoplasm antibodies-associated vasculitis and membranous nephropathy as well as anti-GBM occurring de novo after renal transplantation. Moreover, patients can present with isolated pulmonary haemorrhage as well as with negative tests for circulating anti-GBM. Virtually all patients with anti-GBM disease have autoantibodies that react with two discrete epitopes on the a3 chain of type IV collagen. Recent evidence suggests that healthy persons have low-affinity natural antibodies reacting with the same epitopes, but most people are protected from developing disease-causing high-affinity autoantibodies by human leukocyte antigen-dependent regulatory T-cells (Tregs). The a3 chain-derived peptides presented by the HLA-DR15 antigen lack the ability to promote the development of such Tregs. The detection of anti-GBM in circulation using the rapid assay test has led to early diagnosis and improved prognosis. However, our present tools to curb the inflammation and to eliminate the assaulting antibodies are insufficient. Only about one-third of all patients survive with functioning native kidneys. More effective therapies need to be developed; agents that inhibit neutrophil recruitment, deplete B cells and cleave immunoglobulin G (IgG) in vivo may become new weapons in the arsenal to combat anti-GBM disease.
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D E F I N I T I O N A N D E P I D E M I O L O G Y
Anti-glomerular basement membrane (anti-GBM) disease, according to the Chapel Hill consensus conference nomenclature, is defined as a small-vessel vasculitis affecting glomerular capillaries, pulmonary capillaries or both, with anti-GBM autoantibody deposition along the GBM [1] . Goodpasture's disease, anti-GBM nephritis and rapidly progressive glomerulonephritis type 1 refer to the same disease entity, even though the definitions have varied and have been used with varying stringency [2] [3] [4] . There is a male predominance in most case series; however, the sex difference has diminished from 9:1 in early series [5] to just >50% in more recent publications [6, 7] . Anti-GBM disease is rare and three recent studies from the Netherlands, Ireland and New Zealand have estimated the annual incidence to be around 1.5 per million inhabitants [8] [9] [10] .
T Y P I C A L C L I N I C A L P R E S E N T A T I O N O F A N T I -G B M D I S E A S E
The most common presentation is that of rapidly progressive glomerulonephritis. Haematuria is prominent and sometimes macroscopic, while proteinuria varies from mild to nephrotic range [11] . The fall in glomerular filtration rate is often dramatic, and doubling of serum creatinine can occur within few days [12] . Patients commonly experience unspecific prodromal symptoms for a few weeks before diagnosis consisting of malaise, fatigue, weight loss and low-grade fever [13] . Some patients, however, do not report any symptoms until their renal function has completely ceased. Such patients present with acute renal failure with oliguria, water overload and uraemia. The typical histological finding is crescent formation, often massive, comprising 90-100% of all glomeruli [14] . Contrary to pauci-immune renal vasculitis, where crescents are generally of varying age, crescents in anti-GBM are often at the same stage of development.
Along with glomerulonephritis, pulmonary haemorrhage is also common, resulting in what is called renopulmonary syndrome. In fulminant cases, this leads to respiratory failure, necessitating mechanical respiratory assistance. In recent studies, overt pulmonary symptoms are reported in 20-40% of cases (Table 1) , while a higher proportion can be found in older series [11] . In milder cases, or early in the course, cough is a common symptom; pulmonary engagement can sometimes only be visualized by radiographic examination or by alveolar lavage [15] . In some cases, a severe microcytic anaemia is the only prominent consequence of alveolar bleeding. Overt pulmonary symptoms are more common in smokers [15] , and decreasing prevalence of smoking in industrialized countries may account for the trend towards a lower proportion of pulmonary engagement in recent reports. Lung symptoms, often intermittent, may precede the detection of glomerulonephritis by several months, but concomitant pulmonary and renal disease development is also common. Late pulmonary haemorrhage can also occur and may be precipitated by water overload and anticoagulant therapy for dialysis.
A T Y P I C A L V A R I A N T S A N D S U B G R O U P S

Isolated lung disease and IgG4 anti-GBM
Patients with pulmonary disease and normal renal function can be found in most case series [6, 7, 11, 14, 15] . Many, though not all, have microscopic haematuria or proteinuria. The true incidence of isolated pulmonary haemorrhage due to anti-GBM antibodies is impossible to discern, as most case series stem from nephrology units [20] . We recently reported on a group of patients with severe lung engagement and relatively mild or no renal disease [21] . This group consisted of young female smokers who had mainly anti-GBM autoantibodies of the immunoglobulin G4 (IgG4) subclass. Their autoantibodies exhibited atypical epitope specificity, and half of the patients experienced relapses, necessitating maintenance treatment. Similar cases have been reported from the USA and China [22, 23] .
Nephrotic syndrome and membranous nephropathy overlap
A minority of patients with anti-GBM disease present with nephrotic syndrome. In such cases, the histological appearance may mimic that of membranous nephropathy. There are also cases where anti-GBM disease and membranous nephropathy develop sequentially [24] . In a recent report, eight cases were investigated immunochemically in detail [25] . All patients had circulating antibodies reacting with the typical target for anti-GBM antibodies, the none collagenous domain 1 (NC1 domain) of type IV collagen, even though there were minor differences in subclass distribution and fine epitope specificity compared with patients with typical anti-GBM disease. On the other hand, none of the patients had antibodies to the phospholipase A 2 receptor seen in most cases of primary membranous nephropathy. Compared with typical anti-GBM patients, those with membranous changes had more proteinuria, fewer crescents and lower serum creatinine at diagnosis.
Vasculitis overlap and ANCA/anti-GBM double positivity
A significant proportion of patients with anti-GBM disease has anti-neutrophil cytoplasm antibodies (ANCAs) detected in serum at presentation; myeloperoxidase ANCA is more common than proteinase 3 ANCA [8, 13, 26] . The proportion of patients who test double-positive for anti-GBM and ANCA varies between 21% and 47% in different series, tending to be higher in recent publications (Table 1 ). There are also reports on the sequential development of anti-GBM and ANCA, either with ANCA preceding anti-GBM disease or patients with a previous history of anti-GBM disease developing ANCAassociated vasculitis [27] . Double-positive patients exhibit, at least on a group level, features of both diseases [13] . Such patients have more prominent prodromal symptoms, which often extend over a longer period [6] [7] [8] . On histology, they tend to exhibit more sclerotic glomeruli and more tubulointerstitial fibrosis [26] . Both these findings are compatible with a lower rate of progression, which increases the chance of detection before all glomeruli have been permanently damaged. The possible benefit of early recognition is counteracted by a lower degree of reversibility, which could explain why double positivity has been reported as both a positive and a negative factor with respect to renal survival [6, 8, 17] . Double-positive patients have a greater risk of relapse compared with patients who are positive for anti-GBM only [13, 17] ; this has a bearing on decisions regarding maintenance therapy.
Post-transplant anti-GBM disease
Mutations in the GBM-specific type IV collagen genes COL4A5/A4/A3 lead to Alport syndrome. COL4A4/A3 is located on chromosome 2 leading to autosomal inheritance, whereas COL4A5 is located on the X chromosome leading to sex-linked inheritance [28] . After renal transplantation, type IV collagen chains may provoke alloreactivity with production of antibodies that deposit in the graft. Such alloantibodies can be an incidental finding in a renal biopsy, but can also lead to glomerulonephritis and graft failure [29] . The risk of overt post-transplant anti-GBM disease seems to be dependent on the type of genetic abnormality, and in a recently published series, the risk was <2% [30] . The risk is greater with mutations leading to total absence of the gene product. The antigen specificity of the circulating antibodies can vary and is not always picked up by commercial assays [31] . If a kidney is lost due to post-transplant anti-GBM disease, then there is a high risk for rapid and severe recurrence after re-transplantation [29] .
D E T E C T I O N O F A N T I -G B M
A diagnosis of anti-GBM disease is based on the presence of anti-GBM antibodies in conjunction with renal and/or pulmonary disease. Anti-GBM antibodies can be detected when kidney-bound by direct immunofluorescence (IF) on a biopsy specimen, or circulating autoantibodies by solid-phase methods.
Detection of anti-GBM by serological examination
There are several commercially available kits on the market using either recombinant antigen(s): the non-collagenous domain 1 of the a3 chain of type IV collagen [a3(IV)NC1], purified a3(IV)NC1 from bovine tissue or a combination of both. The performance of the assays is dependent on the quality and purity of the antigen. In most studies, anti-GBM assays are found to have very high specificity and sensitivity [32] although lower values have been reported [33] . Several studies have shown that a negative test for circulating antibodies can be due to atypical antigen or epitope specificity, or atypical IgG subclass [21] . In such cases, the western blot procedure can be an alternative method for detecting anti-GBM antibodies; data from several case reports show that it can detect autoantibodies in samples that are negative in enzyme-linked immunosorbent assay (ELISA). Western blot also has the advantage that it can, to some degree, demonstrate antigen specificity. This is helpful in cases when commercial kits give borderline results and histological confirmation is not possible, or when negative ELISA results are found in patients with a linear IgG staining. However, western blots are in-house assays and not available in most labs.
Detection of anti-GBM by histology
In direct IF microscopy on sections from a renal biopsy, the typical finding is a linear IgG staining along the GBM, often accompanied by C3 deposition. This method can give positive results in cases of diabetes nephropathy and in biopsies from renal transplants without any signs of glomerulonephritis. Other staining patterns are sometimes seen, especially in mild cases with preserved renal function, but also in cases with severely damaged glomeruli.
Anti-GBM can also be detected using indirect IF. In this method, serum from the patient is overlaid on a section of normal kidney. Pre-made ready-to-use sections from primate kidneys are commercially available. A good substrate and a trained pathologist are needed since unspecific staining can be difficult to distinguish from the true linear staining pattern. Low levels of circulating autoantibodies can usually be not detected with indirect IF.
In most cases, both histology and solid-phase assays give the same result, but occasionally only one is positive, making the situation unclear. Several technical and autoantibody-specific reasons generating false-positive or -negative results are discussed above. However, sometimes the conflicting results are true. A negative ELISA and positive IF could be explained by a longer half-life (months) of tissue-bound antibodies compared with circulating ones (weeks). Another possible explanation is that the anti-GBM antibodies bind to an antigen other than a3(IV)NC1 present in the GBM but not included in the solidphase assays. To date, no such antigens have been identified.
A N T I B O D Y -M E D I A T E D T I S S U E D E S T R U C T I O N
When antibodies bind to their antigen, they increase their affinity to Fc-receptors and will thereby activate leukocytes. The default response of activated granulocytes is an attempt to phagocyte the opsonized object. In the case of anti-GBM disease, the entire vessel wall is coated with antibodies and the granulocytes, unable to phagocyte, will throw out their granular content, including several proteases, and degrade the surrounding tissue (Figure 1 ). Nishi et al. [34] have shown that human neutrophils were directly captured by immobilized IgG antibodies under physiological flow conditions through FccRIIA interactions. The presence of autoantibodies bound to the antigen at the inflamed sites indicates that this is the major pathological factor in anti-GBM disease. Numerous animal models have been published showing the pathogenic role of the anti-GBM antibodies. In a classic experiment, primates developed glomerulonephritis after injection of autoantibodies eluted from the kidneys of a nephrectomized patient suffering from anti-GBM disease [35] . Temporal relationships between relapse and reoccurrence of autoantibodies have also been reported. The level of circulating anti-GBM antibodies, as measured by ELISA, has been shown to have prognostic importance [6, 36, 37] .
B-cell epitope
The immune response is polyclonal, and autoantibodies are mainly found against the a3(IV)NC1. Two major epitopes have been identified, named EA and EB [37] [38] [39] . Most patients also have autoantibodies against other epitopes on the a3(IV)NC1 as well as other a(IV) chains [40, 41] . However, only autoantibodies against the EA epitope reflect the toxicity of the autoantibodies [38] . Such antibodies are present at low levels and with low affinity in healthy persons [42] , but the epitope is a cryptotope and conformational changes are necessary for the anti-GBM antibodies to bind. The cryptic properties have been shown to be due to cross-linking via disulfilimine bonds within the NC1 hexamer [43] . Anti-GBM antibodies with high affinity could themselves induce the necessary conformational change and bind to the antigen without denaturation [37] .
T-cell epitope and human leukocyte antigen
In addition to the autoantibodies, there is clear evidence of an important T-cell component of anti-GBM disease. Immunization with certain peptides from the a3(IV)NC1 can cause florid glomerulonephritis without measurable levels of anti-GBM antibodies [44, 45] . The IgG subclass distribution of human anti-GBM indicates a T-cell-mediated immunization, and a mononuclear interstitial cell infiltrate, consisting of mostly CD4 þ T cells, is without exception seen in renal biopsies.
A strong link between anti-GBM disease and human leukocyte antigen (HLA)-DRB1*1501 in particular has been repeatedly reported, and a negative link has been found to HLA-DR7 and DR1, thus acting protectively [4, 46] . Most reports derive from Caucasian populations where the DRB1-15 antigen is found in 70-80% of patients, compared with 20-30% of the controls. In line with immunization with a T-cell epitope, Ooi et al. [47] found that immunization with recombinant a3(IV)NC1 in a DRB1*1501 transgenic mouse also induced anti-GBM disease. A mechanistic basis for the protective role of DR1 was proposed by the same group, who elegantly showed that T cells stimulated with HLA-DR15 loaded with an a3(IV) peptide induced conventional CD4 þ T cells producing proinflammatory cytokines. However, stimulation with the same peptide on HLA-DR1 induced Tregs producing tolerogenic cytokines and the Tregs conferred resistance to disease also in the presence of HLA-DR15, hence explaining the protective role of DR1 [48] (Figure 1) .
T R E A T M E N T O F A N T I -G B M D I S E A S E
Standard therapy for anti-GBM disease consists of a combination of corticosteroids, cyclophosphamide and plasma exchange. The rationale is to reduce inflammation, stop production of autoantibodies and remove those autoantibodies already formed. The use of these therapeutics is not supported by randomized trials-instead, it relies largely on historical comparisons and on results obtained in studies on other forms of vasculitis and glomerulonephritis.
Corticosteroids
Corticosteroids have been used to treat anti-GBM disease for >50 years. Early experience suggested it to be helpful in controlling lung haemorrhage, but without effect on renal disease [5] . Nevertheless, it is still considered an essential part of therapy for anti-GBM disease, due to its effect on neutrophils. Recently, an oral C5a receptor antagonist was reported to be able to replace corticosteroids in a Phase II study in ANCAassociated vasculitis. Drugs interfering with the complement system may in future make it possible to reduce steroids also in anti-GBM disease [49] .
Cyclophosphamide and other immunosuppressants
The use of cyclophosphamide in anti-GBM disease was probably informed by the success of this agent in treating lupus nephritis and granulomatosis with polyangiitis. Without a cytotoxic agent, autoantibody production tends to linger on for months, delaying renal transplantation [11] . At least in combination with plasma exchange, patients do reach low levels of anti-GBM more quickly [3] . Pusey et al. [50] showed that cyclophosphamide could reduce the period of autoantibody production in mercury chloride-induced anti-GBM disease in rats. Mycophenolate mofetil and azathioprine have been used as alternatives to cyclophosphamide, but data are scarce and there are no trials or case series showing that they are effective in reducing autoantibody production or improving outcomes. Data from the Data from the Rituximab in ANCA-Associated Vasculitis (RAVE) trial suggest that rituximab is more efficient than cyclophosphamide in stopping autoantibody production in ANCA-associated vasculitis [51] . There are some reports on the use of this agent in treatment of anti-GBM disease, but its relative efficacy cannot be discerned [7, 52] .
Reduction of circulating autoantibodies
The introduction of plasma exchange in the 1970s was accompanied by a dramatic shift in prognosis, at least for patients with severe lung haemorrhage or renal disease detected early [3, 12, 53] . Plasma exchange is typically administered daily until autoantibodies are undetectable or at least close to the detection level [54] . This may take several weeks to achieve [3] , and it is prudent to keep in mind that plasma exchange removes not only antibodies, but also cytokines, cellular debris and immune complexes. In order to achieve a more rapid decline in autoantibody levels, immunoadsorption has been attempted for anti-GBM disease. This was first reported in 1985 for a case of therapy-resistant pulmonary haemorrhage [55] . In a randomized study of immunoadsorption in various forms of rapidly progressive glomerulonephritis, none of the three anti-GBM patients experienced renal survival [56] ; a recent case series suggests that double filtration plasmapheresis achieved similar results to immunoadsorption [57] . However, a case series from Austria presents three examples of reversal of dialysis dependency with such treatment [58] .
The staphylococcal enzyme IdeS rapidly cleaves all subclasses of human IgG, and it has recently been employed to remove alloantibodies and enable transplantation in HLAimmunized renal transplant recipients [59] . In an animal model, we could show that IdeS cleaved kidney-bound anti-GBM in mice, thereby preventing subsequent damage in this disease model [60] . A prospective clinical trial (EudraCT number: 2016-004082-39) is ongoing to test whether IdeS is a safe and effective therapeutic agent in treating human anti-GBM disease.
O U T C O M E S O F A N T I -G B M D I S E A S E
From being fatal within a few months 60 years ago, survival rates have increased dramatically with immunosuppression, plasma exchange and dialysis. Most recent series report a 1-year patient survival of 80-90% (Table 1) . However, many studies have excluded patients not given a standardized treatment regimen, double-positive patients or those without renal biopsy, thus introducing a bias towards greater chance of survival. Studies based on serology databases, also including patients who were never referred from local hospitals and where renal biopsy has been contraindicated, usually report worse outcomes compared with studies on biopsy-proven cases from large tertiary centres. The overall renal survival in the studies presented in Table 1 is 26% and is strongly dependent on renal function at diagnosis. For those diagnosed with a glomerular filtration rate >15 mL/min, the majority retain independent renal function, while most of those diagnosed later, especially those with anuria, very rarely become free from dialysis. A recent study showed that renal prognosis has improved in recent years, but this is mainly an effect of earlier detection [7] .
C O N C L U S I O N
Recent evidence suggests that all individuals have natural antibodies reacting with the GBM, but that most of us are protected from developing high-affinity autoantibodies by HLA-dependent Tregs. In recent years, the detection of anti-GBM autoantibodies in circulation by rapid assay has led to early recognition and improved prognosis. However, our current tools to curb the inflammation and to eliminate the assaulting antibodies are insufficient. 
